非小细胞肺癌：EGFR基因突变：20外显子插入：汇总🔢

EGFR Exon 20 insertions	Agent	ORR(95% CI)	PFS/DFS,月(95% CI)	PFS,HR(95% CI)	OS,月(95%CI)	OS,HR(95% CI)
CHRYSALIS-1	Amivantamab (second-line and laterlines)	40% (29–51)	8·3 (6·5–10·9)	NA	22·8 (14·6–NE)	NA
PAPILLON	Amivantamab plus 化疗 vs 化疗	73% (65–80)	12·9 (11·4–16·7)	0·38 (0·29–0·51)	NE	NE
WU-KONG6	Sunvozertinib	61% (50–71)	NE	NA	NE	NA

Meyer ML, Fitzgerald BG, Paz-Ares L, Cappuzzo F, Jänne PA, Peters S, Hirsch FR. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet. 2024 Aug 24;404(10454):803-822. doi: 10.1016/S0140-6736(24)01029-8. Epub 2024 Aug 6. PMID: 39121882.